An update to the American Radium Society’s appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiotherapy and oncology 2025-01, Vol.202, p.110640, Article 110640
Hauptverfasser:	Tom, Martin C., Nagpal, Seema, Palmer, Joshua D., Breen, William G., Pollom, Erqi L., Lehrer, Eric J., McGranahan, Tresa M., Shiue, Kevin, Chundury, Anupama, McClelland III, Shearwood, Saeed, Hina, Chang, Eric L., Chiang, Veronica L.S., Wang, Tony J.C., Knisely, Jonathan P.S., Chao, Samuel T., Milano, Michael T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Astrocytoma Brain Neoplasms - drug therapy Brain Neoplasms - pathology Glioma - drug therapy Glioma - pathology Grade 2 glioma Humans IDH inhibitor Isocitrate Dehydrogenase - antagonists & inhibitors Isocitrate Dehydrogenase - genetics Neoplasm Grading Oligodendroglioma Practice Guidelines as Topic Societies, Medical United States Vorasidenib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2–3 glioma.
ISSN:	0167-8140 1879-0887 1879-0887
DOI:	10.1016/j.radonc.2024.110640